- Medicon Valley
- News & Events
- News
- Events
- Medicon Valley Newsletter
- June 2008
- May 2008
- April 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- June 2006
- May 2006
- April 2006
- March 2006
- February 2006
- January 2006
- November 2005
- October 2005
- September 2005
- Business Opportunities
- Science & Research
- Networks
- Services & Support
- Companies & Institutions
- At Your Service
Medicon Valley Biomedical Newsletter
The Medicon Valley Biomedical Newsletter is intended for decision makers in pharmaceutical and biotech companies, investors and other professionals who wish to keep updated on business related activities in the Medicon Valley.
January
The Medicon Valley Biomedical Newsletter January edition is brought to you by Region Skåne and Copenhagen Capacity. The The top story this month is that Action Pharma has signed a financing agreement with new and existing investors, raising a total of EUR 15 million.
Find more information about this and other top news from Medicon Valley in the newsletter below.
-
Action Pharma Raises EUR 15 Million from Investors
23 Jan 2008
Action Pharma A/S has announced that it has signed a financing agreement with new and existing investors, raising a total of EUR 15 million. Swiss/German Global Life Science Ventures and Scandinavian ...
-
BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204
22 Jan 2008
BioInvent International AB has announced that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of BI- 204, a potential treatment for cardiovascular con...
-
Genmab Reaches Milestones in Ofatumumab Collaboration
22 Jan 2008
Genmab A/S has announced that it has reached the second and third development milestones for ofatumumab under the terms of its collaboration with GlaxoSmithKline. The second milestone payment of the c...
-
Santaris Pharma and GlaxoSmithKline Enter Global R&D Alliance
28 Dec 2007
Santaris Pharma A/S and GlaxoSmithKline, GSK, has announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialisation of novel medicines against v...
-
TopoTarget’s Savene Recommended Treatment for Anthracycline Extravasation
14 Jan 2008
TopoTarget A/S has announced that Savene has been recommended as standard treatment for anthracycline extravasation in the new European Oncology Nursing society, EONS guidelines. The guidelines offer ...
{8053793F-3166-4B6E-8652-7EC10793C5C7}.pdf
Medicon Valley Biomedical Newsletter is published by
Region Skåne and Copenhagen Capacity.
We assist foreign companies in finding locations and partnerships in Medicon Valley. We offer free assistance at each step of the business development phase. Visit www.mediconvalley.com or contact us to learn more about the opportunities that await your company in Medicon Valley.
|
Copenhagen Capacity |
Region Skåne |
If you have any comments on the Medicon Valley Biomedical Newsletter please contact the editor at info@mediconvalley.com.
Here you can subscribe to the Medicon Valley Academy Newsletter
The MVA newsletter is an e-mail news service for Medicon Valley Academy (MVA) members and other actors within life science. The newsletter brings you information on new MVA initiatives and activities, editorials on issues of topical interest, news from the region together with available jobs and relevant life science events.
Click here to subscribe or visit www.mva.org.